Zai Lab leverages partnerships and regulatory expertise to commercialize innovative drugs in China, reducing trial risks and accelerating market entry. A robust pipeline with multiple anticipated product launches each year, driving strong revenue growth toward a $1.5–$2 billion target by 2028. The company's strong balance sheet and diverse product portfolio minimize risk.
Zai Lab Limited (NASDAQ:ZLAB ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - President and Chief Operating Officer Rafael Amado - President, Head of Global Research and Development Yajing Chen - Chief Financial Officer Jonathan Wang - Chief Business Officer Conference Call Participants Michael Yee - Jefferies Louise Chen - Scotiabank Yen-Der Li - Leerink Partners Li Watsek - Cantor Yigal Nochomovitz - Citi Anupam Rama - JPMorgan Jack Lin - Morgan Stanley Rebecca Liang - Bernstein Linhai Zhao - Goldman Sachs Operator Hello, ladies and gentlemen, thank you for standing by, and welcome to Zai Lab's First Quarter 2025 Financial Results Conference Call. At this time, all participants are in listen-only mode.
Although the revenue and EPS for Zai Lab Limited (ZLAB) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
11 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
6 May 2025 Date | | - Cons. EPS | - EPS |
25 Feb 2025 Date | | - Cons. EPS | - EPS |
12 Nov 2024 Date | | - Cons. EPS | - EPS |
5 Nov 2024 Date | | - Cons. EPS | - EPS |
11 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
6 May 2025 Date | | - Cons. EPS | - EPS |
25 Feb 2025 Date | | - Cons. EPS | - EPS |
12 Nov 2024 Date | | - Cons. EPS | - EPS |
5 Nov 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Ying Du CEO | NASDAQ (NMS) Exchange | 98887Q104 Cusip |
CN Country | 1,869 Employees | - Last Dividend | - Last Split | 20 Sep 2017 IPO Date |
Zai Lab Limited is a biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing a broad range of therapies. The company focuses on treating a variety of conditions including oncology, autoimmune disorders, infectious diseases, and neuroscience disorders. Headquartered in Shanghai, China, Zai Lab has established multiple license and collaboration agreements with leading pharmaceutical companies worldwide to expand its product portfolio and research capabilities. These collaborations enable the company to leverage revolutionary technologies and compounds to address unmet medical needs in various therapeutic areas.
Zai Lab Limited's product pipeline includes:
In addition to these products, Zai Lab actively engages in research and development through collaborations with companies such as Tesaro, Inc., Deciphera, Paratek Bermuda Ltd., and argenx to enrich its pipeline and enhance treatment options available to patients worldwide.